CEO of Omni Bio.

The Diabetes Patent and other patents and patent applications that Omni Bio licenses for the treatment for the treatment of new indications with AAT. James Crapo, CEO of Omni Bio, commented, ‘We are very pleased with the grant of the patent diabetes, anti-inflammatory properties with our first type 1 diabetes clinical trial combines excited, we believe, potentially afford Omni Bio a commercial opportunity. It strengthens our belief that AAT may, by its anti-inflammatory properties to be highly effective in the treatment of diabetes and other inflammatory diseases.

Alnylam Publishes Results from Phase II GEMINI study with ALN – RSV01Alnylam Pharmaceuticals , a leading RNAi therapeutics company announced that it results from the Phase II GEMINI study in the Proceedings of published the National Academy of Sciences . This data, which presented at the presented at the International Symposium on Respiratory Viral Infections in Singapore in 2008 showed human proof of concept with an RNAi therapeutic in a randomized, double-blind, placebo-controlled study. In this study , treatment with ALN – RSV01 statistically significant antiviral activity, including a reduction in RSV infection rate and an increase in the number of persons free of infection. Free of infection.Antiacne receives two additional NIH Grant for the development of Topical Therapeutics.

Signum Biosciences , was issued recently two Small Business Innovation Research Phase I by National Institute of Arthritis and MSD and Skin Diseases award , a division of the the NIH, total value of through $ 684,000 to the development of new G protein – coupled receptor modulating agents developing to. Shared treat skin disorders.

O $ 600,000 degree paying by the Health Research Council did established that lot physicians to place the blame husbands the establishment producing medicine without regarding their impact for she.